Sovaldi – Record Breaking Sales More Than Doubled Forecast!

Gilead Sciences Inc has seen record-breaking sales of its new Hepatitis C drug, Sovaldi, with over $2 Billion in the first quarter- the highest EVER for a new medicine. Read more here. (Source: Deena Beasley, Reuters, 4/22/14).

You might also be interested in:

State Treasurers Call Out Gilead for Putting Remdesivir… 09/21/2020
Trump's "Buy American" Executive Order Could Raise Drug Prices 08/06/2020
Gilead Pricing of Remdesivir is "Immoral", Says Pennsylvania's… 08/07/2020
New Simulation Determines Max Cost for Cost-effective Health… 11/06/2020
Drugmakers Hope to Trump International Pricing Plan with… 08/26/2020
2020 CADTH Symposium Issues Call for Late-Breaking Abstracts 02/15/2020
ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic… 02/20/2020